Burden of Illness of Adult Patients with Metastatic Colorectal Cancer Bearing the KRAS P.G12C Mutation - A Systematic Literature Review

Author(s)

Chen Z1, Rehn M2, Eichinger C3, Majer I4
1Amgen, Tampa, FL, USA, 2Amgen, Thousand Oaks, CA, USA, 3Oxford PharmaGenesis, Oxford, UK, 4Amgen, Rotkreuz, Switzerland

OBJECTIVES: Colorectal cancer (CRC) is the third most common type of cancer and a leading cause of death worldwide. KRAS p.G12C mutation has been identified as a putative oncogenic driver in several types of solid tumors and is estimated to occur in approximately 3% of CRC patients.

METHODS: A systematic literature review was conducted following the PRISMA 2020 guideline to consolidate the evidence on the epidemiological, real-world clinical, economic and humanistic burden in patients with CRC harboring the KRAS mutation (including KRAS p.G12C) who have either (1) progressed or experienced disease recurrence on or after at least two prior lines of therapy, or (2) progressed or experienced disease recurrence on or after therapy with a triplet drug combination consisting of fluoropyrimidine, irinotecan and oxaliplatin given for mCRC.

RESULTS: Of the 1885 identified citations, 27 primary publications were included. Most publications (n=17) reported clinical outcomes; 3 of them presented evidence in KRAS p.G12C-mutated patients. The prevalence of KRAS p.G12C was reported to be 1.8% to 6% in patients with mCRC (n=5), and 5% to 21.2% in patients with KRAS mutations (n=4). Patients with KRAS p.G12C mutation mainly received chemotherapy with or without bevacizumab regardless of the line of therapy (n=1). Treatment patterns did not differ significantly from patients with other KRAS mutations. Patients with KRAS p.G12C mutated mCRC had numerically shorter median OS than other mCRC genotypes (n=2). Median PFS were similar across KRAS p.G12C mutated and non-mutated patients (n=1). Economic evaluations reported outcomes related to testing for KRAS mutations. No evidence was found for humanistic burden in the target population.

CONCLUSIONS: There is a substantial lack of economic and humanistic evidence for the target population. In addition, there is limited availability and generalizability of data on real-world clinical outcomes for patients with KRAS p.G12C mutated mCRC .

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

EE155

Topic

Economic Evaluation

Disease

Gastrointestinal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×